Literature DB >> 16923022

Characterization of binding properties of ICAM-1 peptides to LFA-1: inhibitors of T-cell adhesion.

Meagan E Anderson1, Bimo A Tejo, Tatyana Yakovleva, Teruna J Siahaan.   

Abstract

In the present study, we characterized the binding site of two intercellular adhesion molecule-1-derived cyclic peptides, cIBC and cIBR, to the LFA-1 on the surface of T cells. These peptides had been able to inhibit LFA-1/intercellular adhesion molecule-1 signal by blocking the signal-2 of immune synapse. Both peptides prefer to bind to the closed form of LFA-1 I-domain, indicating that two peptides act as allosteric inhibitors against intercellular adhesion molecule-1. Binding site mapping using monoclonal antibodies proposes that cIBC binds to around residues 266-272 of LFA-1 I-domain where this site is adjacent to the metal ion-dependent adhesion site. On the other hand, cIBR binds to the pocket called L-site where is distant from metal ion-dependent adhesion site. Cross-inhibition mapping between two peptides show that cIBR could inhibit the binding of cIBC but not vice versa, suggesting that cIBR has some properties that allow this peptide bind to more than one site. Structural comparison between cIBC and cIBR reveals that cIBR is more flexible than cIBC, allowing this peptide bind to exposed region, such as cIBC-binding site as well as cramped pocket like L-site. Our findings are important for understanding the selectivity of cIBC and cIBR peptides; thus, they can be conjugated with drugs and transported specifically to the target.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16923022     DOI: 10.1111/j.1747-0285.2006.00407.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  8 in total

1.  Methotrexate (MTX)-cIBR conjugate for targeting MTX to leukocytes: conjugate stability and in vivo efficacy in suppressing rheumatoid arthritis.

Authors:  Sumit Majumdar; Meagan E Anderson; Christine R Xu; Tatyana V Yakovleva; Leo C Gu; Thomas R Malefyt; Teruna J Siahaan
Journal:  J Pharm Sci       Date:  2012-04-26       Impact factor: 3.534

2.  cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells.

Authors:  Chuda Chittasupho; Prakash Manikwar; Jeffrey P Krise; Teruna J Siahaan; Cory Berkland
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

Review 3.  Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases.

Authors:  Mario E G Moral; Teruna J Siahaan
Journal:  Curr Top Med Chem       Date:  2017       Impact factor: 3.295

4.  Effect of modification of the physicochemical properties of ICAM-1-derived peptides on internalization and intracellular distribution in the human leukemic cell line HL-60.

Authors:  Sumit Majumdar; Bimo A Tejo; Ahmed H Badawi; David Moore; Jeffrey P Krise; Teruna J Siahaan
Journal:  Mol Pharm       Date:  2009 Mar-Apr       Impact factor: 4.939

5.  Controlling immune response and demyelination using highly potent bifunctional peptide inhibitors in the suppression of experimental autoimmune encephalomyelitis.

Authors:  P Kiptoo; B Büyüktimkin; A H Badawi; J Stewart; R Ridwan; T J Siahaan
Journal:  Clin Exp Immunol       Date:  2013-04       Impact factor: 4.330

6.  Solution structure of a novel T-cell adhesion inhibitor derived from the fragment of ICAM-1 receptor: cyclo(1,8)-Cys-Pro-Arg-Gly-Gly-Ser-Val-Cys.

Authors:  Bimo A Tejo; Teruna J Siahaan
Journal:  Biopolymers       Date:  2009-08       Impact factor: 2.505

7.  Structural modifications of ICAM-1 cyclic peptides to improve the activity to inhibit heterotypic adhesion of T cells.

Authors:  Bimo A Tejo; Usman S F Tambunan; Gennady Verkhivker; Teruna J Siahaan
Journal:  Chem Biol Drug Des       Date:  2008-06-11       Impact factor: 2.817

8.  Improving Brain Delivery of Biomolecules via BBB Modulation in Mouse and Rat: Detection using MRI, NIRF, and Mass Spectrometry.

Authors:  Kavisha R Ulapane; Ngoc On; Paul Kiptoo; Todd D Williams; Donald W Miller; Teruna J Siahaan
Journal:  Nanotheranostics       Date:  2017-06-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.